We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In choppy markets, combining technical and fundamental strength becomes paramount. Below are 3 stocks that hold these characteristics and are on the verge of breaking out:
DXCM
Dexcom ((DXCM - Free Report) ) is a medical device company that designs and develops continuous glucose monitoring (CGM) systems. CGMs are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients.
Unique Product Leads to Strong Growth
Dexcom’s unique monitoring system is used to continuously measure a patient’s blood glucose level and transmit that information to a small cell phone-sized receiver in real-time. Though the blood glucose monitoring Dexcom is highly competitive, DXCM is the leader. Last quarter, EPS grew 113% year-over-year on revenue growth of 18%.
Image Source: Zacks Investment Research
The company’s EPS of $0.17 beat Zacks estimates of 15 cents by 13.3%. The positive surprise was nothing new. DXCM has a strong history of beating estimates – in 17 out of the last 19 quarters, the company has surprised to the upside.
Image Source: Zacks Investment Research
“The Longer the Base, The Higher in Space”
A stock that has sound fundamentals and breaks out from a long base can produce robust results. DXCM fits the criteria – the stock is emerging from a consolidation dating back to October 2022. Should the breakout hold, expect fireworks to the upside in the coming weeks.
Image Source: Zacks Investment Research
With diabetes rates increasing in the U.S. and worldwide, DXCM should benefit from solid healthcare tailwinds.
RMBS
Rambus ((RMBS - Free Report) ) is an industry-leading chip producer. The company’s chips are used for interface, memory, security, and display architectures for computing, gaming, graphics, and more.
Strong Industry
From a performance, growth, and price performance perspective, the leading industry in the stock market today is the chip sector. Though Rambus may get less attention than Advanced Micro Devices ((AMD - Free Report) ) or Nvidia ((NVDA - Free Report) ), the company has strong growth and even more robust price and volume action.
Fundamentals
RMBS has grown top and bottom-line results at a double-digit clip for several quarters in a row, and the stock’s strong Zacks #2 (Buy) ranking suggests that may continue.
Price & Volume
The most intriguing part of RMBS is its strong price and volume action. RMBS has been hugging the 50-day moving average for all of 2023. The recent post-eps pullback and subsequent rebound off the 50-day moving average is a golden opportunity, in my opinion.
Image Source: Zacks Investment Research
VIPS
Zacks Rank #1 (Strong Buy) stock Vipshops ((VIPS - Free Report) ) is China’s third largest e-commerce platform. Vipshops benefits from the massive market it serves (300 million customers) and the many companies it counts as partners (more than 20,000).
The End of China’s Zero-Covid Policy
China had one of the most stringent COVID-19 lockdown policies in the entire world. In fact, at times, Chinese President Xi was willing to allow the Chinese economy to come to a screeching halt to tamp down coronavirus cases. Throughout this time, Vipshops and most other Chinese companies suffered. However, in the past three quarters, VIPS has turned around its EPS picture and has grown EPS by 12%, 55%, and 27%. Despite the widely publicized reopening of the Chinese economy, analysts seem slow to change course. VIPS has delivered positive surprises in four straight quarters, including big beats of 42.31% and 33.33%.
Image Source: Zacks Investment Research
Finally, it appears that analysts are catching on to Vipshop’s renewed growth trajectory. In the past seven days, Zacks Consensus Estimates for 2023 and 2024 have been revised higher.
Technical View
When searching for a monster stock, two of the most powerful traits to look for are a strong uptrend and relative strength. VIPS holds both of these characteristics. Over the past year, the stock is up 91.1% while the S&P 500 Index is +2.9% - impressive when considering the volatility that occurred in global markets.
Image Source: Zacks Investment Research
The stock has been consolidating for the past five months and is pulling into the rising 50-day moving average – an attractive reward-to-risk zone. VIPS is scheduled to report earnings Wednesday.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
3 Stocks on the Verge of Breaking Out
In choppy markets, combining technical and fundamental strength becomes paramount. Below are 3 stocks that hold these characteristics and are on the verge of breaking out:
DXCM
Dexcom ((DXCM - Free Report) ) is a medical device company that designs and develops continuous glucose monitoring (CGM) systems. CGMs are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients.
Unique Product Leads to Strong Growth
Dexcom’s unique monitoring system is used to continuously measure a patient’s blood glucose level and transmit that information to a small cell phone-sized receiver in real-time. Though the blood glucose monitoring Dexcom is highly competitive, DXCM is the leader. Last quarter, EPS grew 113% year-over-year on revenue growth of 18%.
Image Source: Zacks Investment Research
The company’s EPS of $0.17 beat Zacks estimates of 15 cents by 13.3%. The positive surprise was nothing new. DXCM has a strong history of beating estimates – in 17 out of the last 19 quarters, the company has surprised to the upside.
Image Source: Zacks Investment Research
“The Longer the Base, The Higher in Space”
A stock that has sound fundamentals and breaks out from a long base can produce robust results. DXCM fits the criteria – the stock is emerging from a consolidation dating back to October 2022. Should the breakout hold, expect fireworks to the upside in the coming weeks.
Image Source: Zacks Investment Research
With diabetes rates increasing in the U.S. and worldwide, DXCM should benefit from solid healthcare tailwinds.
RMBS
Rambus ((RMBS - Free Report) ) is an industry-leading chip producer. The company’s chips are used for interface, memory, security, and display architectures for computing, gaming, graphics, and more.
Strong Industry
From a performance, growth, and price performance perspective, the leading industry in the stock market today is the chip sector. Though Rambus may get less attention than Advanced Micro Devices ((AMD - Free Report) ) or Nvidia ((NVDA - Free Report) ), the company has strong growth and even more robust price and volume action.
Fundamentals
RMBS has grown top and bottom-line results at a double-digit clip for several quarters in a row, and the stock’s strong Zacks #2 (Buy) ranking suggests that may continue.
Price & Volume
The most intriguing part of RMBS is its strong price and volume action. RMBS has been hugging the 50-day moving average for all of 2023. The recent post-eps pullback and subsequent rebound off the 50-day moving average is a golden opportunity, in my opinion.
Image Source: Zacks Investment Research
VIPS
Zacks Rank #1 (Strong Buy) stock Vipshops ((VIPS - Free Report) ) is China’s third largest e-commerce platform. Vipshops benefits from the massive market it serves (300 million customers) and the many companies it counts as partners (more than 20,000).
The End of China’s Zero-Covid Policy
China had one of the most stringent COVID-19 lockdown policies in the entire world. In fact, at times, Chinese President Xi was willing to allow the Chinese economy to come to a screeching halt to tamp down coronavirus cases. Throughout this time, Vipshops and most other Chinese companies suffered. However, in the past three quarters, VIPS has turned around its EPS picture and has grown EPS by 12%, 55%, and 27%. Despite the widely publicized reopening of the Chinese economy, analysts seem slow to change course. VIPS has delivered positive surprises in four straight quarters, including big beats of 42.31% and 33.33%.
Image Source: Zacks Investment Research
Finally, it appears that analysts are catching on to Vipshop’s renewed growth trajectory. In the past seven days, Zacks Consensus Estimates for 2023 and 2024 have been revised higher.
Technical View
When searching for a monster stock, two of the most powerful traits to look for are a strong uptrend and relative strength. VIPS holds both of these characteristics. Over the past year, the stock is up 91.1% while the S&P 500 Index is +2.9% - impressive when considering the volatility that occurred in global markets.
Image Source: Zacks Investment Research
The stock has been consolidating for the past five months and is pulling into the rising 50-day moving average – an attractive reward-to-risk zone. VIPS is scheduled to report earnings Wednesday.